Wells Fargo Initiates Coverage On Definium Therapeutics with Overweight Rating, Announces Price Target of $68
Benzinga Newsdesk 3 months ago
NewsInitiationAnalyst RatingsPrice Target
Wells Fargo analyst Benjamin Burnett initiates coverage on Definium Therapeutics (NASDAQ:DFTX) with a Overweight rating and announces Price Target of $68.
Wells Fargo analyst Benjamin Burnett initiates coverage on Definium Therapeutics (NASDAQ:DFTX) with a Overweight rating and announces Price Target of $68.